NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.)

NTLAのニュース

   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   John M. Leonard Sells 109,889 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock  2021/02/05 09:24:43 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 109,889 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $64.00, for a total transaction of $7,032,896.00. Following the completion of the sale, the chief executive officer now owns 575,488 shares of the company’s […]
   Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/01/08 16:51:48 Investing.com
Raymond James Stick to Their Buy Rating for Intellia Therapeutics
   Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/01/08 16:51:48 Investing.com
Raymond James Stick to Their Buy Rating for Intellia Therapeutics
   Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021  2021/01/07 12:30:00 GlobeNewswire
Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR)Anticipates…
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   CRISPR Technology Market Growing Demand to Impact Revenue Share by 2030 | Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation  2020/12/08 11:56:42 OpenPR
The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0% since 2015. The market is expected to grow from $685.5 million in 2019 to $1,654.2
   The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut  2020/12/03 12:46:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …
   CRISPR Technology Market Growing Demand to Impact Revenue Share by 2030 | Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation  2020/12/08 11:56:42 OpenPR
The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0% since 2015. The market is expected to grow from $685.5 million in 2019 to $1,654.2
   The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut  2020/12/03 12:46:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …
   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   Intellia Therapeutics Announces Third Quarter 2020 Financial Results  2020/11/05 12:30:00 GlobeNewswire
On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR), following regulatory authorization to…

calendar